COTA

“Improving outcomes for cancer patients starts with answering a simple question: Do our data and tools reflect the people we treat?” C. K. Wang, MD, Chief Medical Officer at COTA, discusses representation in clinical trials and the consequences when our trials and datasets aren’t representative of all patients and their treatment in the real-world. The combination of real-world data and AI can be key in bridging representation gaps and harnessing insights that will improve outcomes for all patients, not just those historically represented in research. Read his full perspective in HIT Consultant Media: https://lnkd.in/e9uchRfT

Nearly 4M women worldwide are diagnosed with breast or gynecological cancers each year. Yet too many factors around these diseases are still poorly understood, including why there are so many disparities and variances in treatment and outcomes. Real-world data can tell the story of breast, ovarian and uterine cancers at a pivotal moment in women’s health: 1?? “???????????????? ???????????? ???????????? ???? ?????? ?????????????? ?????? ???????? ?????????? ?????? ?????????? ???? ???????? ???????????? ?????????? ???????? ???? ????????-?????????? ????????????????,” explained C. K. Wang, MD, an oncologist and COTA’s Chief Medical Officer. 2?? “???? ???????? ???????? ???????????????? ???????????? ???????? ???????????? ???????????? ???????????? ???? ????????????????, ?????? ???????? ???? ???? ?????????? ?????? ?????????????? ?????? ?????????????????? ???????? ?????? ?????????????? ???????????? ????????????????????. ?????? ???? ???????? ???????? ???????????? ?????? ???????? ?????????? ???? ???????? ?????????????? ????????????????????, ???????????????? ?????????????? ???????????????? ??????????????????, ???? ?????????? ???????? ????????????.” 3?? “???? ???????? ?????? ???????????????????? ???? ?????????????????? ???????? ?????????????????????? ???????? ???????? ?????? ???????? ?????????? ???? ???????? ???? ?????? ???????? ???????? ???????????????? ???????????? ?????????? ????????????. ?????? ?????????????? ???? ???? ???? ????????, ???????????????????? ???? ???????????????? ?????????? ???? ?????????? ???????????? ??????????’?? ?????????????? ???????? ???????? ???????????????????????? ???????? ???????? ?????????????????? ???????? ?????????? ????????????????????.” At COTA, our goal is to develop a structured patient journey that follows every patient’s oncology experience from diagnosis until the conclusion of the treatment journey. This data can be used for multiple purposes, from understanding trends in disease prevalence to getting a better look at disparities in care, such as treatment delays, unwanted variation in therapy, or the influence of socioeconomic factors on outcomes. By furthering our investment in women’s cancer datasets, COTA is eager to collaborate with industry partners on accelerating research into these conditions with the goal of improving experiences and outcomes for the hundreds of thousands of women affected by cancer every year. #realworlddata #oncologyresearch #cancerresearch #breastcancer #ovariancancer #womenshealth

It was a who’s who in pharma and healthcare this week with both #GenAI4pharma and Shaper Capital’s AI in Healthcare Summit happening in San Francisco. There has never been a more critical time for business leaders and policy experts to come together to discuss how we responsibly use technology to improve care for ALL patients. Thanks to Shwen Gwee and Travis May for hosting these meaningful events. ?? Miruna Sasu Noga Leviner David Shulkin Mandy Cohen Aneesh Chopra DJ Patil Josh Harder Sahir Raoof

After more than 14 years working closely with life science companies, clinical researchers, regulators, and oncologists to clean and curate complex hematologic cancer data, we’re setting our sights on solid tumors to bring a new level of clarity and understanding to the cancer community.? Our datasets now include longitudinal treatment and outcomes data for a broad array of solid tumors, including: ?? Breast cancer ?? Colon cancer ?? Rectal cancer ?? Gastric cancer ?? Lung cancer ?? Melanoma ?? Ovarian cancer ?? Pancreatic cancer ?? Prostate cancer ?? Uterine cancer These are conditions that touch millions of patients and their families every year, and generate huge amounts of data that can be used to better understand critical genetic, clinical, and socioeconomic patterns in disease development, progression, treatment, and outcomes. After taking on so many tough problems in the unique liquid tumor space, we are eager to bring that deep expertise to solid tumor data.? We’re excited about the possibilities of applying these well-honed strategies to larger and more diverse datasets to assist with the precision medicine approaches of the future. With so many patient records and so many rich data elements available to us in the solid tumor environment, our data teams will be able to further assist researchers and life science companies with developing highly detailed and specific patient cohorts to support faster, more efficient, and more effective investigations. It’s the natural next step toward a world where every person with cancer gets the tailored, informed, and effective care they need to have the best possible outcome.? #realworlddata #oncologyresearch #cancerresearch #cancercare

C. K. Wang, MD writes in HIT Consultant Media that too often, clinical data tells incomplete stories of how cancer and its treatments affect specific patient groups. Diverse and inclusive real-world data can help us address these gaps as part of a multifaceted approach. https://lnkd.in/e9uchRfT #realworlddata #oncologyresearch

At COTA, we believe that the power of Real-World Data (RWD) can transform cancer care, and we’re on a mission to make that vision a reality. We're looking for an ambitious VP, Life Sciences who shares that passion and is eager to bring high-quality COTA data and research services to mid-size and emerging biotechnology and medical diagnostic companies. This role is for a strategic hunter who thrives in building new business opportunities and establishing strong relationships with life science partners. At COTA, we don’t just pride ourselves on our industry-leading data; our people are what truly set us apart. You’ll work alongside a team of passionate, innovative and expert professionals who share a deep commitment to advancing cancer care and improving patient outcomes. If you're eager to make a lasting impact, work with the best, and help shape the future of oncology, we want to hear from you.

?????????????????? ???????????????????? ????????????????????: ?????? ?????????????? ???? ???????????????? ???????????????? ?????? ?????????????????? The future of healthcare is being shaped by the latest breakthroughs in obesity treatment, oncology data analytics, and clinical trials. Here are some key highlights: ?????????????????? ????????????????????: - Dr. Steffen-Sebastian Bolz discusses Aphaia’s novel oral coated glucose formulation for obesity treatment, focusing on minimizing side effects through physiological mechanisms. - Miruna Sasu, President & CEO of COTA Healthcare, shares insights on using real-world data (RWD) to enhance drug development and improve patient outcomes. ???????????????????? ???????????????? & ????????????????: - The 2025 SCOPE Summit explored the integration of RWD in clinical trials, emphasizing regulatory initiatives, trial design innovation, and real-world applicability. - The MSK Innovation Hub Challenge showcased the evolution of decentralized clinical trials (DCTs) through collaborative strategies. ???????????????? ?????????? ????????: - Y-mAbs Therapeutics' Phase 2 trial data in Nature Communications showcases the safety and efficacy of naxitamab combined with GM-CSF for high-risk neuroblastoma. - Celldex Therapeutics’ preclinical data on CDX-622 indicates potential advantages over single-target therapies in treating inflammation and fibrosis. - Garuda Therapeutics raised $50 million in Series A-1 funding to advance off-the-shelf hematopoietic stem cell (HSC) therapies for blood disorders. #ClinicalResearch #HealthcareInnovation #Biopharma #RealWorldData #DrugDevelopment #Oncology #ClinicalTrials #Biotech

EHR data gives us a deep and longitudinal understanding of the patient journey, unlike any other data type. But, in raw form, it's messy and unstructured which has limited its use in research and drug development. Supported by our AI engine, CAILIN, COTA is overcoming these barriers to drive widespread adoption of EHR-sourced #realworlddata. Read more from Brian K. Buntz about our recent milestones reducing the time and cost of curating EHR data in Drug Discovery & Development.

Since the turn of the century, there’s been a growing recognition that the health of our friends, families, & communities is intimately tied to the health of our physical environment. Safe water, clean air, & a diverse, balanced ecosystem are essential conditions for life to thrive & innovation to flourish. As a company focused on cancer care and research, we believe it’s our responsibility to focus not just on the health of the patients we ultimately serve, but on the natural world in which we all live. Sustainability & ecological responsibility are some of our most important corporate values, which help to anchor us in the work we do every day. That’s why COTA has been working closely with our partners in the pharma community to better understand our carbon footprint & other impacts on the environments in which we all live, work, & play. It’s not as easy as it sounds, especially for a distributed, remote team that doesn’t manufacture, ship, or sell physical goods. After all, we don’t have factories or vehicle fleets that produce emissions, & it’s a tall order to quantify the environmental impact of the digital activities completed in hundreds of individual home offices across the country. We've launched an internal sustainability committee of cross-functional leaders to establish our ecological mission statement, begin work on assessing our environmental impact, & collaborate with an external environmental consultant to accelerate our sustainability efforts. We’re working with EcoVadis, a trusted sustainability intelligence platform, to benchmark ourselves in key areas of corporate responsibility, including the environment, labor & human rights, ethics, & the sustainable procurement of goods & services. We’re proud to have earned recognition for our commitment as we continue to gather data & build out our sustainability program & goals. Last but not least, we are investing in developing & meeting science-based targets for our ecological impact, which involves collecting energy use information on our remote team members, corporate headquarters, digital service partners, & more. It’s a complex process with lots of moving pieces, but we know that it’s the little things that can add up to big changes. According to our CEO, Miruna Sasu, “COTA’s primary mission is to bring clarity to cancer care, but we also want to bring clarity to how we’re changing the world from an environmental standpoint. We’re aligned with the life sciences industry in their move toward more sustainable activities, & we’re eager to work with our partners to make positive changes that can ensure this beautiful planet stays healthy & vibrant.” During this crucial time to shed light on these issues, especially as climate change continues to impact the world around us, COTA is dedicated to evaluating & improving our sustainability now & in the future.

Advancements in LLMs will transform the way life science teams analyze medical datasets - reducing the time, effort, and cost to answer routine questions that form the foundations of more advanced scientific queries. Last year, COTA launched ????????????, an oncology trained, on-demand insight generator designed to answer questions related to data analytics, including specific cohort size, subgroup breakdowns, treatment sequencing, and event timing. ???????????? addresses these questions through training on COTA's curated oncology datasets while guided by in-house oncology expertise. It expedites access to data and oncology-specific insights across the pharmaceutical R&D life cycle and, in the near future, will provide additional ways to develop hypotheses and generate evidence. Read more about ????????????'s results below: